BD (BDX) Q1 2026 Financial Results Summary

BD (BDX) Q1 2026 Financial Results Summary

Release Date: February 9, 2026

BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, reported its first-quarter financial results for fiscal year 2026, which ended on December 31, 2025. Below is a detailed summary of the key financial metrics and operational highlights.

Financial Highlights

• Total Revenue:
• $5.3 billion, up 1.6% reported and 0.4% on a foreign currency-neutral basis (FXN) compared to $5.2 billion in Q1 2025.

• New BD Revenue (excluding Life Sciences) increased 2.5% FXN.

• Earnings Per Share (EPS):

• GAAP diluted EPS: $1.34, increased by 28.8% from $1.04 in Q1 2025.
• Adjusted diluted EPS: $2.91, a decrease of 15.2% from $3.43 in Q1 2025.

Segment Details

• U.S. Revenue:

• $3.2 billion, an increase of 2.6% from $3.1 billion in Q1 2025.

• International Revenue:

• $2.1 billion, up 0.2% from $2.1 billion in Q1 2025.

• Revenue by Segment:

• Medical Essentials:
  • $1.6 billion, increasing by 0.6%.
• Connected Care:
  • $1.1 billion, increased by 5.5%.
• BioPharma Systems:
  • $429 million, up by 2.7%.
• Interventional:
  • $1.3 billion, rising by 5.8%.
• Life Sciences:
  • $766 million, down by 8.3%.

Operational Developments

• Combination with Waters Corporation for the Biosciences and Diagnostic Solutions business, expected to close on the same day as the earnings announcement.
• Affirmed FY26 revenue growth guidance, with expected GAAP revenue growth characterized as low single-digit plus.

Expenses and Income

• Total Operating Costs:
• $4.7 billion, a slight decrease of 0.3% from $4.7 billion in Q1 2025.
• Operating Income:
• $552 million, increased by 21.8% from $453 million in Q1 2025.
• Net Income:
• $382 million, up 26.1% compared to $303 million in Q1 2025.

Cash Flow Highlights

• Net cash provided from operating activities: $657 million, down from $693 million in Q1 2025.
• Repurchases of common stock: $250 million, a decrease from $750 million in the same quarter a year ago.
• Dividends paid: $299 million, a slight decrease from $302 million in Q1 2025.

Balance Sheet Metrics

• Total Assets: $54.8 billion, decreased from $55.3 billion at the end of the previous quarter.
• Current debt obligations: $2.6 billion, increased from $1.6 billion.
• Shareholders’ equity: $25.3 billion, slightly decreased from $25.4 billion.

Full Year Fiscal 2026 Outlook

• The company reaffirmed the full-year fiscal 2026 guidance for New BD, projecting low single-digit growth in revenue and an adjusted diluted EPS in the range of $12.35 to $12.65.

Conclusion

BD’s performance in Q1 2026 demonstrates solid growth against a backdrop of strategic initiatives and operational resilience, with a focus on advancing clinical technology and market presence. The company is well-positioned to achieve its fiscal year guidance amid ongoing developments in the healthcare sector.

Here are the extracted tables from the press release:

---